More people were migraine-free during a seven-day span following their first intravenous (IV) infusion with VYEPTI compared to placebo, most as soon as
Day One
On Day One, there was a 52% reduction in the number of people experiencing a migraine, compared to 25% with placebo.
Migraine days may be cut by 75% or more
- 22% of people treated with VYEPTI achieved a 75% reduction of migraine days, compared to 16% treated with placebo, from Months 1 through 3. (This is not a significant difference.)
- 31% of people treated with VYEPTI achieved a 75% or more reduction in migraine days after one month, compared to 20% with placebo.
Most people were migraine-free for a month or more†
- 63% of people treated with VYEPTI were migraine-free for a month or more over a 12-month period, compared to 48% with placebo.
†A migraine-free month was defined as a consecutive 28-day period in which the patient experienced no migraine.
VYEPTI provided a treatment benefit that lasted through Month 6, compared to placebo
Patients received 2 doses of VYEPTI.
*VYEPTI 100 mg is the recommended dose. However, your doctor could decide that you may benefit from a 300 mg dose.
Select safety information
VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.
ARE YOU READY TO BREAK AWAY FROM MIGRAINE?
Start the conversation with your doctor to see if VYEPTI may be right for you.
WELL TOLERATED
In two clinical trials of approximately 1,700 people with migraine, the most common side effects were:
Stuffy nose and scratchy throat
- 6% among people treated with VYEPTI 100 mg
(8% among people treated with VYEPTI 300 mg) - 6% among people treated with placebo
Allergic reactions
- 1% among people treated with VYEPTI 100 mg
(2% among people treated with VYEPTI 300 mg) - 0% among people treated with placebo
Notify your healthcare provider if you become pregnant or plan to become pregnant.
References:
- VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
- Data on file. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
- Silberstein S, Kudrow D, Saper J, et al. Eptinezumab results for the prevention of episodic migraine over 1 year in the PROMISE-1 (PRevention Of Migraine via Intravenous Eptinezumab Safety and Efficacy–1) trial. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society (AHS); June 28-July 1, 2018; San Francisco, CA. PF108LB.
- Saper J, Wilks K, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine through 1 year: results from the phase 3 PROMISE-1 (PRevention Of Migraine via Intravenous Eptinezumab Safety and Efficacy–1) trial. Poster presented at: 71st American Academy of Neurology (AAN) Annual Meeting; May 4-10, 2019; Philadelphia, PA. 538.003.
- Winner P, McAllister P, Cady R, Snapinn S, Hirman J, Kassel E. Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society (AHS); July 11-14, 2019; Philadelphia, PA. P217LB.
IMPORTANT SAFETY INFORMATION
AND APPROVED USE
Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.
APPROVED USE
VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.
VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.
Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.
The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.
These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more information, please see the Prescribing Information and Patient Information.
APPROVED USE
VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
AND APPROVED USE
Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.
VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.
Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.
The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.
These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more information, please see the Prescribing Information and Patient Information.
© 2020 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100034
The product information provided in this site is intended only for residents of the US. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.
You are about to leave the VYEPTI website and open a website operated by a third party. Lundbeck is not responsible for the content of third-party websites.
You are now being directed to a website intended for US healthcare professionals.
Don’t miss out on important information about VYEPTI